Oxford Immunotec (OXFD) 12.10 $OXFD Oxford Immu
Post# of 273318
Posted On: 09/27/2016 5:06:59 AM
Oxford Immunotec (OXFD) 12.10 $OXFD
Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation
Globe Newswire - Thu Sep 01, 6:17AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. Magistrate Judge in the Company's patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings has issued a recommendation denying in substantial part the defendants' motion to dismiss the Company's claims. In issuing his recommendation, the magistrate judge stated, "At this early juncture, the Court concludes that the in vitro aspect of the plaintiff's tuberculosis test is an 'inventive concept' because it improves on prior methods of detecting tuberculosis infection." The magistrate judge's recommendation should now allow the Company to press forward with its case against the three defendants, asserting infringement of its six patents relating to methods for diagnosing TB infection.
DGX: 84.61 (-0.83), OXFD: 12.10 (+0.12)
Oxford Immunotec to Present at the Baird 2016 Global Healthcare Conference
Globe Newswire - Wed Aug 24, 2:15PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Rick Altieri, Chief Financial Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016, at 2:35 p.m. ET at the New York Palace in New York, NY.
OXFD: 12.10 (+0.12)
Oxford Immunotec Reports Second Quarter 2016 Financial Results
Globe Newswire - Tue Aug 02, 6:00AM CDT
- Second quarter revenue of $19.2 million, increased 34% compared to prior year period
OXFD: 12.10 (+0.12)
Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen
Globe Newswire - Thu Jun 23, 3:05PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction expected to close on July 1, 2016.
OXFD: 12.10 (+0.12)
Oxford Immunotec to Present at the Jefferies 2016 Healthcare Conference
Globe Newswire - Fri May 20, 10:45AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET at the Grand Hyatt in New York, NY.
OXFD: 12.10 (+0.12)
Oxford Immunotec reports 1Q loss
Automated Insights - Tue May 03, 7:54AM CDT
ABINGDON, Britain (AP) _ Oxford Immunotec Global PLC (OXFD) on Tuesday reported a loss of $7 million in its first quarter.
OXFD: 12.10 (+0.12)
Oxford Immunotec Reports First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
OXFD: 12.10 (+0.12)
Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
Globe Newswire - Wed Apr 20, 10:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 12.10 (+0.12)
Oxford Immunotec Global appoints Patrick J. Balthrop, Sr. to board
M2 - Tue Feb 02, 3:04AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) revealed on Monday the election of Patrick J. Balthrop, Sr. to its board of directors.
OXFD: 12.10 (+0.12), LMNX: 22.57 (-0.22)
Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors
Globe Newswire - Mon Feb 01, 4:00PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors.
OXFD: 12.10 (+0.12), LMNX: 22.57 (-0.22)
Oxford Immunotec to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thomson Reuters ONE - Tue Jan 26, 11:06AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
OXFD: 12.10 (+0.12)
Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation
Globe Newswire - Thu Sep 01, 6:17AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. Magistrate Judge in the Company's patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings has issued a recommendation denying in substantial part the defendants' motion to dismiss the Company's claims. In issuing his recommendation, the magistrate judge stated, "At this early juncture, the Court concludes that the in vitro aspect of the plaintiff's tuberculosis test is an 'inventive concept' because it improves on prior methods of detecting tuberculosis infection." The magistrate judge's recommendation should now allow the Company to press forward with its case against the three defendants, asserting infringement of its six patents relating to methods for diagnosing TB infection.
DGX: 84.61 (-0.83), OXFD: 12.10 (+0.12)
Oxford Immunotec to Present at the Baird 2016 Global Healthcare Conference
Globe Newswire - Wed Aug 24, 2:15PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Rick Altieri, Chief Financial Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016, at 2:35 p.m. ET at the New York Palace in New York, NY.
OXFD: 12.10 (+0.12)
Oxford Immunotec Reports Second Quarter 2016 Financial Results
Globe Newswire - Tue Aug 02, 6:00AM CDT
- Second quarter revenue of $19.2 million, increased 34% compared to prior year period
OXFD: 12.10 (+0.12)
Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen
Globe Newswire - Thu Jun 23, 3:05PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction expected to close on July 1, 2016.
OXFD: 12.10 (+0.12)
Oxford Immunotec to Present at the Jefferies 2016 Healthcare Conference
Globe Newswire - Fri May 20, 10:45AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET at the Grand Hyatt in New York, NY.
OXFD: 12.10 (+0.12)
Oxford Immunotec reports 1Q loss
Automated Insights - Tue May 03, 7:54AM CDT
ABINGDON, Britain (AP) _ Oxford Immunotec Global PLC (OXFD) on Tuesday reported a loss of $7 million in its first quarter.
OXFD: 12.10 (+0.12)
Oxford Immunotec Reports First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
OXFD: 12.10 (+0.12)
Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
Globe Newswire - Wed Apr 20, 10:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 12.10 (+0.12)
Oxford Immunotec Global appoints Patrick J. Balthrop, Sr. to board
M2 - Tue Feb 02, 3:04AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) revealed on Monday the election of Patrick J. Balthrop, Sr. to its board of directors.
OXFD: 12.10 (+0.12), LMNX: 22.57 (-0.22)
Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors
Globe Newswire - Mon Feb 01, 4:00PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors.
OXFD: 12.10 (+0.12), LMNX: 22.57 (-0.22)
Oxford Immunotec to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thomson Reuters ONE - Tue Jan 26, 11:06AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
OXFD: 12.10 (+0.12)
(0)
(0)